okt 17, 2018: 8:30 a.m. - 9:40 a.m.
In the past three years, the number of U.S. clinical trials testing checkpoint inhibitors in combination immunotherapies has quintupled to nearly 1,300 trials. Two types of therapeutic approaches have tried to demonstrate their value to magnify the successful performance of PD-1/PD-L1 inhibitors as combination partners: IDO inhibitors and oncolytic viruses. The former partner therapy has delivered initial disappointments in the past year, while combining oncolytic viruses with checkpoint inhibitors has seen promising clinical results. This panel reviews the current landscape of checkpoint inhibitor development, highlighting lessons that can be gained from recent achievements and setbacks in combination immunotherapies.%uFFFD
Moderator: Kenneth LaMontagne, PhD, MBA, Vice President, Research TAP (Therapy Acceleration Program), The Leukemia & Lymphoma Society%uFFFD